

### 3.4. Molecular Dynamics

Flexibility of the target binding site is an essential but frequently overlooked aspect to be considered in molecular docking. Enzymes and receptors can undergo conformational changes during the molecular recognition process [97]. In some cases these structural rearrangements are small and the ligand fits in a binding site with little mobility. Otherwise, some proteins undertake significant conformational changes, which can involve elements of secondary and tertiary structure. Such flexibility issues can be handled by the use of techniques such as MD [98].

Usually the ligand stabilizes a subset of several possible conformations of the receptor, shifting the equilibrium toward the minimum energy structures [99]. In such cases, MD simulations can produce alternative conformational states corresponding to these ligand-induced structures. Also, when no suitable crystallographic structures for a particular molecular target are available (*i.e.*, structures with inaccessible or poorly defined binding sites), MD can be applied to generate a set of docking convenient structures [100]. Accordingly, potential conformational states are sampled by MD simulations based on the available crystallographic data, and accessible conformations (*i.e.*, those with accessible and well-defined binding cavities) can be selected for molecular docking [98]. MD can additionally be used to estimate the stability of a ligand-receptor complex proposed by molecular docking [101]. When a MD-generated ligand conformation deviates by more than a given RMSD value from the corresponding docking solution, the predicted ligand-receptor complex can be considered unstable [102].

Molecular dynamics applies Newton's equations of motion, as described in classical mechanics, to specify the position and speed of each atom in the system under study. As a result, the trajectory and temporal evolution of a ligand-receptor complex can be examined [103]. Initially, a specific configuration is attributed to the atoms with the purpose to reproduce the temperature and pressure of the real system. From the computation of the forces acting on each particle, it is possible to determine the position and velocity of each of these atoms at a posterior time. These calculations are repeatedly performed until the molecular trajectories are integrated for a given time interval [98].

The forces acting on the system are determined by molecular interaction potentials, which are usually parameterized by quantum chemical calculations or experimental data. This set of parameters (the force-field), determines the contribution of each type of interaction to the general function [100]. Among the diverse available force-fields, AMBER [104], CHARMM [105] and GROMOS [106], can be highlighted as widely used in molecular dynamics simulations.

Regardless of its usefulness MD has its limitations. Among them, we can stress the high computational cost demanded by the simulation of large systems, which usually consist of thousands of atoms when ligand-receptor complexes are under study. Some of the conformational changes undertaken by receptors during molecular recognition occur on time scales exceeding the available computational capacity [99]. Despite its limitations, MD is able to deliver important contributions to SBDD, especially when combined with other molecular modeling methods, such as molecular docking.

### 3.5. Structural Water

Crystallographic water is a major challenge in molecular docking and SBDD. These molecules are strongly bound to the receptor and observed across several crystallographic structures of a particular

protein [107]. In approximately 65% of the crystallographic protein-ligand complexes, at least one water molecule is involved in ligand-receptor recognition [108]. Usually, structural water is located in deep pockets of the receptor structure and mediates multiple hydrogen bonds between the ligand and the protein binding site [109]. In SBDD and docking campaigns, these molecules can be displaced by the designed ligands or considered as part of the target structure. The release of a crystallographic water molecule from its binding site is entropically favorable; however the process causes a simultaneous loss in enthalpy [109]. To compensate for this enthalpy loss, a specific moiety of the ligand can be designed to mimic the interaction network of the displaced water through the formation of equivalent hydrogen bonds with the protein. Alternatively, structural water can be explicitly included in the docking experiments, allowing the formation of highly favorable hydrogen-bonding networks between the ligand and the target binding site. In this case, a variety of methods are available to evaluate which water molecules are strongly bound and, therefore, suitable for this purpose [107]. Among these strategies one can highlight free energy perturbation calculations using Monte Carlo statistical mechanics simulations, which estimate the binding free energy for a given water molecule, allowing the discrimination between displaceable and strongly-bound structural water [110]. Another strategy is the analysis of geometric parameters of the protein environment surrounding each crystallographic water molecule [111]. One of these methods combines the HINT free energy scoring function [112] and the Rank algorithm, which is a routine that estimates the number and quality of potential hydrogen bonds for a given water molecule [113]. HINT calculates the interaction energy between each crystallographic water molecule and its environment taking into account the chemical properties and accessibility of available hydrogen bond donors and acceptors, as well as the hydrophobic features of the binding site. Rank searches for potential donor and acceptor partners for each water molecule and generates a ranking scheme, ranging from molecules that do not interact via hydrogen-bonding with a non-water element, to molecules that form four geometrically ideal hydrogen bonds. This approach can be used to guide the choice between the replacement of an optimally coordinated structural water molecule—which would require a precisely designed ligand to compensate for the enthalpy loss—or the maintenance of such molecule in the SBDD and docking strategies. Alongside the use of such algorithms, a comparison between structural water in multiple crystal structures should be carried out to minimize the risk of mistakenly discarding or keeping a specific water molecule [109] (strongly bound water is often conserved across multiple crystallographic structures).

### 3.6. Protein-Protein Interaction Inhibitors and Molecular Docking

Cellular and biochemical processes are largely controlled by interactions between different classes of proteins [114]. Many diseases, such as cancer, can be attributed to defective protein-protein interactions (PPIs); therefore, this type of intermolecular event is a highly attractive target in drug discovery [115]. PPI inhibitors can be defined as small-molecule compounds that directly compete with one of the protein partners [116]. The belief that targeting PPIs is an unsuitable strategy in drug design has been challenged by recent successful cases, such as the development AMG-232, a MDM2-p53 inhibitor, currently in Phase II clinical trials for cancer therapy [117]; and maraviroc (Selzentry<sup>®</sup>), a commercially available CCR5-gp120 inhibitor used in AIDS treatment [118].

The major challenge faced by SBDD and molecular docking in the field of PPIs is the identification and characterization of binding sites, as well as the assessment of their potential for interacting with small-molecule compounds [119]. The contact surfaces where two proteins interact with each other are significantly different from ligand-protein binding cavities. Generally, PPI binding sites are relatively flat interfaces that do not have a single large and well-defined pocket; otherwise they consist of a greater number of smaller pockets [119]. Strategies for detection of such binding sites and evaluation of their drugability have been implemented in several computational methodologies, among which one can highlight the freely available web-based tools Q-SiteFinder [120] and ANCHOR [121].


Q-SiteFinder is an energy-based method for the prediction of protein binding sites, found on the assumption that the interaction energy (estimated by a methyl probe) of each interface pocket determines its amenability to SBDD [120]. The distinct pockets at the interface are categorized according to their interaction energy, providing an evaluation of those regions where a ligand could interact and optimize the binding energy. According to this procedure the algorithm generates a volume envelope, which is a region where the calculated van der Waals interaction energy remains below a defined threshold. These volume envelopes indicate the pockets where a putative ligand would engender a favorable interaction with the receptor surface.

The ANCHOR algorithm searches for amino acid side chains deeply buried at protein-protein interfaces (anchor residues) to pinpoint potential binding pockets carrying drugable properties. These anchor sites have the ability to generate a vigorous attraction between the receptor and the ligand, and unlike hotspots, they carry explicit concave/convex surfaces, which is a convenient property for ligand binding. For a particular PPI interface, the method calculates the change in the solvent accessible surface area ( $\Delta$ SASA) upon binding, for each amino acid side-chain, as well as a measure of their contribution to the total interaction free energy [122]. ANCHOR does not categorize the probed residues as anchor or non-anchor; alternatively it provides a ranking of these residues in decreasing order of  $\Delta$ SASA. The top ranked residues may be visualized with the assistance of a web-based tool, which offers an interactive interface for visualization of the properties of the surrounding environment, such as the presence of hydrogen-bonding networks.

A distinct strategy is the use of biochemical and biophysical data to guide the docking process. Information provided by biomolecular NMR spectroscopy has been used to define PPI interfaces and determine the reciprocal orientation of the two binding partners [123]. One of these methods, the HADDOCK approach, employs chemical shift perturbation data produced by NMR titration assays as well as information obtained from mutagenesis experiments, to identify the interacting residues and score the predicted binding conformations [124]. Highly solvent-accessible residues that exhibit a substantial chemical shift perturbation upon binding, are labeled as important residues in the formation of the complex. This information is incorporated into the docking procedure as ambiguous interaction restraints (AIR), which take into account the distance between the interacting atoms of the two binding partners. Through this approach, HADDOCK explores all potential configurations around the PPI interface and finds the most favorable pairs of interacting atoms. The method allows side chain flexibility at the PPI interface, which is a key aspect to improve the accuracy of the results. Another useful feature of the HADDOCK methodology is a final refinement step, in which explicit interfacial water molecules are incorporated into the docking protocol to optimize the binding energetics.

#### 4. Virtual Screening (VS)

Virtual screening is the application of *in silico* methods for selecting promising compounds from chemical databases [125]. It can be regarded as the computational counterpart of experimental biological evaluation methods, such as high-throughput screening (HTS) [126]. In drug discovery, the use of large and chemically diverse compound libraries for computational and biological screening is one of the most widespread strategies [127]. This has stimulated the use of VS as a fast and cost-effective method for the evaluation of a variety of compound collections. Usually, VS strategies fall into two main types: (i) ligand- and (ii) structure-based virtual screening (LBVS and SBVS, respectively, Figure 5) [128].



**Figure 5.** The SBVS and LBVS approaches. Virtual compound databases can undergo different filtering procedures. In SBVS approaches, the three-dimensional structure of the molecular target is employed to identify compounds compatible with the properties of the target binding site. In pharmacophore modeling, compound collections are employed to generate structural patterns that should be present in active compounds. In LBVS studies, molecular descriptors known to be relevant for biological activity are used as selection criteria to identify suitable compounds for experimental evaluation.

##### 4.1. Ligand-Based Virtual Screening (LBVS)

Although this review focuses on structure-based methods, it is worth mentioning that most of the current virtual screening studies combine SBVS and LBVS methods. A number of reviews on LBVS methods are available in the literature [129,130].

LBVS is based on the exploration of molecular descriptors gathered from compounds known to be active [129,131]. In general, a set of mutual characteristics of a compound series is identified, which are subsequently applied as molecular filters. These database filtering methods are used to select compounds for experimental evaluation and reduce the chemical space to be explored in further screening steps. Several freely available software packages accurately estimate molecular descriptors for database filtering. These programs are useful in predicting important properties related to biological activity, such as solubility, protonation state and molecular volume [132]. Table 3 lists some chemoinformatics tools used to estimate relevant molecular properties.

**Table 3.** Widely used software packages for the prediction of molecular descriptors related to biological activity.

Software
Molinspiration [133,134]
OSIRIS Property Explorer [134,135]
Molsoft [136]
MoKa [137,138]

Another LBVS approach is the use of structural features collected from known ligands to generate pharmacophore models [139]. These ligand-based 3D pharmacophore models consist of a compilation of structural properties thought to be relevant for biological activity. Generating a 3D pharmacophore model involves the following typical steps: (i) exploring the conformational space of the compound series; (ii) identifying reciprocal properties; (iii) aligning the molecules according to the identified properties; and (iv) generating the pharmacophore model. A critical issue that needs to be addressed by current pharmacophore construction algorithms is the development of an effective molecular alignment tool [140]. Table 4 lists several commercial and academic pharmacophore construction programs.

**Table 4.** Examples of programs for pharmacophore generation.

Commercial	Academic
Hiphop [141]	PharmaGist [154,155]
HypoGen [141]	ALADDIN [156]
HypoRefine [141]	RAPID [157]
GASP [142,143]	DANTE [158]
DiscoTech [143,144]	APOLLO [159]
GALAHAD [143,145]	CLEW [160]
LigandScout [146,147]	MPHIL [161]
MOE [148,149]	GAMMA [162]
PHASE [150,151]	SCAMPI [163]
XED [152,153]	Apex-3D [164]
	LigBuilder [165,166]

#### 4.2. Structure-Based Virtual Screening (SBVS)

In SBVS, the compound database is docked into a previously selected target binding site [167]. Along with the prediction of the binding mode, SBVS provides a ranking of the docked molecules. This ranking can be used as the sole criterion for selecting promising molecules, or it can be combined with other evaluation methods. The selected compounds are experimentally evaluated to determine their biological activity on the molecular target under investigation [168].

In general, SBVS consists of the following steps: (i) molecular target preparation; (ii) compound database selection; (iii) molecular docking; and (iv) post-docking analysis. Rigorous review of the available information regarding the target and known ligands, as well as a careful analysis of the advantages and pitfalls of the selected docking algorithms, are required in delineating the most appropriate strategies [169].

It is generally the case that several structures of a given receptor are available. If the target is available in either apo and holo forms, both should be considered in the SBVS strategy. Conformational changes, resulting from interaction with ligands, and structural resolution are important details requiring consideration in the selection of the most suitable structure [170,171]. Next, the selected structure undergoes several procedures to properly prepare it for the molecular docking studies. In short, the preparation routine consists of adding hydrogen atoms, eliminating water molecules (with the exception of those mediating important interactions), specifying the correct protonation and tautomerization states of the binding site residues, and calculating partial charges [172].

Another important step is the preparation of the small-molecule compound collection. Databases that gather, into a single site, a large number of chemical suppliers and a wide diversity of chemical data are widely used in SBVS [173]. Usually, these compound collections operate as interactive interfaces for searching and selecting compound subsets according to predetermined chemical filters. Usually, database compounds are stored as line notations, such as SMILES, SMARTS and InChI, which are then converted into three-dimensional molecular structures. Converting the original files requires the correct assignment of stereochemistry, partial charges, and ionization states [174]. Table 5 provides some examples of well-established virtual databases used in virtual screening.

**Table 5.** Chemical databases used in virtual screening.

<b>Database</b>
Zinc [175,176]
PubChem [177,178]
ChemSpider [179,180]
ChEMBL [181,182]
NuBBE DB [183,184]
ChemBank [185,186]
eMolecules [187]
DrugBank [188,189]
Binding DB [190,191]

In a following step, the prepared database is docked into the target binding site. The conformational search algorithm explores the energy landscape of each molecule and high-scoring compounds are selected as potential ligands [169–172]. As virtual screening involves hundreds of thousands (or millions) of compounds, post-docking analysis is usually conducted to decide which compounds to prioritize. Visualizing the predicted ligand-receptor complexes is very useful for this purpose, allowing the analyses of critical aspects, such as the presence of specific intermolecular interactions [192]. Another facet that can be assessed through visualization of the predicted structures is whether the solutions match predetermined requirements, such as pharmacophore hypotheses. A list of molecular modeling programs used for visualizing SBVS results is provided in Table 6.

**Table 6.** Programs for graphical display of SBVS and molecular docking results.


Program
UCSF Chimera [193,194]
VMD [195,196]
Pymol [197,198]
BALL [199,200]
RasMol [201,202]
Jmol [203]
JSmol [204]

## 5. Molecular Docking and Structure-Based Drug Design Studies

Molecular docking is a well-established and widely used methodology in drug design. A substantial number of studies are available in which a diverse array of approaches has been applied for the discovery of novel bioactive molecules. Recent cases involving different docking strategies combined with other molecular modeling methods are examined next.

### 5.1. Discovery of *Mycobacterium tuberculosis* InhA Inhibitors Using SBVS and Pharmacophore Modeling


Trans-enoyl-ACP reductases are NADH-dependent enzymes involved in fatty acid biosynthesis. The enzyme from *Mycobacterium tuberculosis* (InhA) promotes the synthesis of long-chain fatty acids, namely mycolic acids, which are an essential component of the bacterial cell wall [205]. An important enzyme in tuberculosis drug discovery, InhA is the molecular target for the tuberculostatic drug isoniazid [206]. The compound is a pro-drug that loses its hydrazine group as it reacts with the enzyme cofactor NADH, forming an isonicotinic-acyl-NADH complex that inhibits the catalytic activity of InhA (Figure 6).



**Figure 6.** (A) Structure of the tuberculostatic drug isoniazid; (B) The isonicotinic-acyl moiety covalently bound to NADH in the binding site of InhA (PDB 1ZID, 2.70 Å). The protein backbone is represented as a cartoon. The isonicotinic-acyl fragment (carbon in yellow) and NADH (carbon in white) are shown as sticks.

In a recent study, a series of novel InhA inhibitors was identified through a virtual screening strategy. The authors employed a multistage approach, integrating pharmacophore modeling and molecular docking [207]. First, a four-point 3D pharmacophore model was generated by superimposing 36 InhA

crystallographic structures available in the PDB. Next, an analysis of the enzyme binding site (PDB 1P44, 2.70 Å) (Figure 7A) was conducted to identify a set of structural properties for use as molecular filters. According to this analysis, the ZINC database was filtered by applying the following rules:  $4 < \log P < 7$ ; number of rotatable bonds  $< 6$ ; number of hydrogen bond acceptors  $< 8$ ; polar surface area  $< 40 \text{ \AA}^2$ ;  $250 \text{ Da} < \text{molecular weight} < 400 \text{ Da}$ . The resulting dataset containing 999,853 molecules underwent two screening procedures: (i) a pharmacophore-based VS; and (ii) a SBVS employing four molecular docking programs.



**Figure 7.** (A) The crystallographic structure of the InhA homotetramer (PDB 1P44, 2.70 Å); (B) The structure and activity of the InhA inhibitors identified using the pharmacophore modeling and SBVS approaches.

The filtered database was subjected to a flexible search using the 3D pharmacophore model and the database searching program UNITY [208]. A group of compounds matching the pharmacophore hypothesis (*i.e.*, those assigned with the highest UNITY scores) was docked into the InhA binding site using the molecular docking program Gold. This program was chosen because it was able to predict the crystallographic poses of known ligands with high accuracy. The solutions were visually inspected and those molecules matching all of the four pharmacophore spots were selected for further analysis.

In parallel with the pharmacophore-based approach, the database (999,853 compounds) was docked into the InhA binding site using Gold. The 100 top scored compounds were subjected to a SBVS using three other molecular docking programs (AutoDock, FlexX and Surflex-Dock) to acquire a consensus score.


After a detailed analysis of the results obtained with both strategies (pharmacophore-based and structure-based VS), six ligands were evaluated for their activity on purified InhA. Three molecules, having  $IC_{50}$  and  $K_i$  values in the micromolar range, were identified as suitable starting points for further ligand optimization studies in tuberculosis drug discovery (Figure 7B).

## 5.2. Discovery of Proteasome Inhibitors by SBVS

The proteasome plays an essential role in eukaryotic metabolism by promoting the degradation of damaged and unnecessary proteins [209]. This protein complex also controls the progression of the cell cycle, an aspect that led to its development and validation as a molecular target for cancer drug discovery. Two proteasome inhibitors, carfilzomib, a peptidic natural product derivative, and bortezomib, a boronic acid-based compound, have been successfully used in the treatment of refractory multiple myeloma.




The discovery and development of such chemotherapeutic agents represented a significant advance in the therapy of the disease [210]. Figure 8 depicts the structure of carfilzomib and bortezomib and their crystallographic structures in complex with the 20S proteasome.



**Figure 8.** (A) Structure of the proteasome inhibitor carfilzomib; (B) Crystallographic structure of the human 20S proteasome complexed to carfilzomib (PDB 4R67, 2.89 Å). The protein backbone is in cartoon representation. The ligand (carbon in salmon) and residues in the active site (carbon in yellow) are shown in stick representation. Water is shown as red spheres and hydrogen bonds are indicated as dashed lines; (C) Structure of the proteasome inhibitor bortezomib; (D) Crystallographic structure of a yeast 20S proteasome complexed to bortezomib (PDB 2F16, 2.80 Å). The ligand (carbon in cyan) is shown in stick representation.

A SBVS strategy was employed to identify novel proteasome inhibitors from an *in-house* database containing 345,000 compounds at the University of Cincinnati [210]. This compound collection was evaluated by applying a rigid molecular docking algorithm implemented in the FRED program. The molecules were ranked through consensus scoring using distinct force-field-based functions and the most highly scored compounds were additionally checked for specific binding conformations. Finally, 288 molecules were selected and evaluated for their activity on purified human 20S proteasome.

Of the 288 tested compounds, 19 were found to be active as proteasome inhibitors. These results led to further studies in which the inhibitor G4 (Figure 9A) emerged as a promising molecule capable of inhibiting the replication of cancer cells *in vitro* ( $IC_{50} = 7 \mu\text{M}$ ). Compound G4 was also used as a reference structure from which a series of derivatives was designed. This approach resulted in the identification of compound G4-1 (Figure 9B) as a lead proteasome inhibitor with attractive drug-like properties. This compound stands out for its excellent metabolic stability compared to the currently marketed proteasome inhibitors carfilzomib and bortezomib.




**Figure 9.** Structures of G4 (A) and G4-1 (B), the most potent proteasome inhibitors identified by SBVS. Remaining CT-L (chymotrypsin-like) activity at 10  $\mu$ M: 9.69% for G4 and 6.15% for G4-1.

### 5.3. Identification of a New Series of STAT3 Inhibitors by VS

Signal transducers and transcription activators (STATs) are transcription factors activated by phosphorylation and dimerization. STAT dimers bind to recognition motifs in DNA, thereby promoting gene transcription [211]. This event triggers signal transduction pathways that regulate many biological processes including cell survival, growth and differentiation. Among the seven STAT isoforms, STAT3 has been investigated as a molecular target for cancer drug discovery. In neoplastic cells, STAT3 disarticulates the correct expression of transcription factors, cell cycle regulators and angiogenesis factors, inducing the transformation of benign tumors into malignant cells [212].

Recently, a series of novel STAT3 dimerization inhibitors was discovered through an SBVS campaign [213]. A database containing millions of compounds was filtered for drug-like properties, resulting in a final collection of approximately 360,000 molecules, which was then used in the SBVS. The crystallographic structure of the STAT3- $\beta$  dimer (PDB 1BG1, 2.25 Å) (Figure 10A) was elected as the receptor for the docking studies. The most promising compounds were selected by applying a consensus scoring method called CONSENSUS-DOCK, implemented in the molecular docking program DOCK4. This methodology estimates the energetics of ligand-receptor binding by combining three scoring functions: DOCK4, FlexX and PMF.

Consensus scoring and visual inspection of the ligand-receptor complexes were used for the selection of potential inhibitors. Through this process, 136 molecules were evaluated for their ability to inhibit STAT3 dimerization. Compound STX-0119, a quinolone-carboxamide derivative (Figure 10B), was the most active STAT3 dimerization inhibitor. Studies using fluorescence resonance energy transfer (FRET) assays confirmed that STX-0119 acts by disrupting STAT3 dimerization. *In vivo* studies in mice models showed the ability of the compound in suppressing the replication of lymphoma cells, indicating the suitability of STX-0119 for further medicinal chemistry studies.




**Figure 10.** (A) Structure of STAT3-β in complex with DNA (PDB 1BG1, 2.25 Å). The protein backbone is in cartoon representation (purple). The DNA strand is shown in green (deoxyribose), blue (purine and pyrimidine bases) and red (phosphates); (B) Structure of the STAT3 dimerization inhibitor STX-0119 identified by molecular docking studies.

#### 5.4. Discovery of Pim-1 Kinase Inhibitors by a Hierarchical Multistage VS

Serine-threonine kinase proviral insertions in murine (Pim-1) plays an important role in cell proliferation and differentiation. The enzyme promotes cell cycle progression, regulating essential signaling pathways such as janus kinase/signal transducer and activator of transcription (JAK/STAT) [214]. Similarly to other kinases involved in cell cycle regulation, Pim-1 has been studied as a potential molecular target for cancer drug R & D. Abnormal levels of Pim-1 have been correlated to the genesis of hematopoietic and solid tumors such as lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, and prostate and breast cancers [215]. The enzyme has also been implicated in the conversion of benign neoplasms into malignant tumors and in the emergence of drug resistance [215,216].


Novel Pim-1 inhibitors were discovered by applying a combination of ligand- and structure-based filtering methods [216]. Four compound libraries, approximately 20 million molecules in all, were employed in a hierarchical multistage virtual screening strategy. Three molecular modeling approaches were used sequentially: (i) support vector machine modeling (SVM); (ii) pharmacophore construction; and (iii) molecular docking (Figure 11).

First, a SVM model was built using a training set of almost 37,500 compounds and a group of 50 molecular descriptors including geometrical, topological, and electronic properties. The reliability of the model was confirmed by the attainment of a prediction accuracy of approximately 99% for the training set and 90% for an external test set. This SVM classification model was used as an initial filtering stage wherein the complete database (20 million compounds) was reduced to 56,583 molecules. In the following screening step, a pharmacophore-based strategy was employed. A 3D pharmacophore hypothesis (defined by one hydrogen-bond acceptor, one hydrogen-bond donor and one hydrophobic spot) was built according to eight highly potent Pim-1 inhibitors. This ligand-based pharmacophore model was employed to evaluate the output of the SVM screening, resulting in a subset of 10,631 compounds.




**Figure 11.** Scheme of the multistage VS approach. Four compound collections were combined yielding a database containing approximately 20 million compounds. Three computational screening procedures were applied and followed by visual inspection. The overall process resulted in the selection of 47 compounds for biochemical evaluation.

Finally, this enriched database was subjected to a SBVS procedure. The molecular docking program Gold and the crystallographic structure of Pim-1 complexed to a pyridazine inhibitor (PDB 3BGQ, 2.00 Å) (Figure 12) were used in the virtual screening stage. The 935 most highly scored compounds were selected for visual inspection, from which 47 molecules were chosen for *in vitro* biochemical assays. The overall VS strategy identified five compounds as novel Pim-1 inhibitors (Figure 13). The study demonstrated the successful integration of ligand- and structure-based approaches in the discovery of suitable hits for further development of new chemotherapeutic agents.



**Figure 12.** (A) Crystallographic structure of Pim-1 kinase complexed to the inhibitor VX2 (PDB 3BGQ, 2.00 Å). The protein backbone is in cartoon representation. The inhibitor (carbon in orange) is shown as ball-and-sticks; (B) Structure of the Pim-1 inhibitor VX2.



**Figure 13.** Structures and biological activity data for the Pim-1 inhibitors identified in the ligand- and structure-based VS strategy.


### 5.5. Identification of Aldose Reductase Inhibitors by MD and SBVS

Human aldose reductase (ALR2) is a NADPH-dependent oxidoreductase that catalyzes the reduction of glucose to sorbitol [217]. This is a key reaction in the polyol pathway of glucose metabolism, a process implicated in the long-term complications of diabetes. Hyperglycemia induces overexpression of ALR2, leading to an increase in sorbitol concentration, which ultimately causes osmotic imbalance, alterations in membrane permeability, oxidative stress, and finally tissue damage [218]. Accordingly, the enzyme has been extensively studied as a molecular target for the treatment of diabetes complications. Several ALR2 inhibitors have entered clinical trials. Currently, epalrestat (Kinedak<sup>®</sup>) is marketed in Japan as an ALR2 inhibitor for the treatment of diabetic neuropathy [219].

In a recent investigation, novel ALR2 inhibitors were discovered by an approach incorporating MD simulations and SBVS studies [219]. The binding site of the enzyme undergoes large conformational changes and adopts distinct configurations upon binding different classes of ligands. This variability imposes an additional difficulty in the characterization of a unique and well-defined binding site appropriate for molecular docking studies. To address this issue, potentially accessible binding site conformations were sampled by MD simulations based on the available crystallographic structures of ALR2. After this procedure, three average conformations were selected for the SBVS campaign. Figure 14 shows one of the crystallographic structures of ALR2 used in the MD simulations. The enzyme is complexed to the inhibitor IDD594 (PDB 1US0, 0.66 Å).


A database containing more than 7200 compounds was docked against the three representative structures using the molecular docking program FlexX. Approximately 1200 highly scored compounds were retained and subsequently subjected to protein-ligand interaction analysis. This analysis was based on an intermolecular interaction fingerprinting method, by which a set of 128 molecules were selected for the next screening stage. The ligand-receptor complexes of these compounds underwent MD

simulations, and 71 molecules with RMSD values less than 3.00 Å from the docking conformation were selected for biochemical evaluation.



**Figure 14.** (A) Crystallographic structure of ALR2 complexed to the inhibitor IDD594 and the enzyme cofactor NADP<sup>+</sup> (PDB 1US0, 0.66 Å). The protein backbone is in cartoon representation. The inhibitor (carbon in magenta) and NADP<sup>+</sup> (carbon in white) are shown as sticks; (B) Structure of the ALR2 inhibitor IDD594.

Experimental validation revealed 15 novel ALR2 inhibitors having IC<sub>50</sub> values in the micromolar or nanomolar range (Figure 15). The most potent inhibitors demonstrated biological activity comparable to the marketed ALR2 inhibitor epalrestat (IC<sub>50</sub> = 0.24 μM). Some of these compounds also showed ALR2/ALR1 selectivity and cytotoxicity comparable to epalrestat. These data demonstrate the value of the discovered compounds, which can be considered as promising candidates for diabetes drug discovery.



**Figure 15.** Structures and biological activity data for the ALR2 inhibitors identified by the VS strategy. Epalrestat (Kinedak<sup>®</sup>), a commercially available ALR2 inhibitor is also shown.

### 5.6. Design of Selective Cyclooxygenase-2 Inhibitors


Cyclooxygenase-2 (COX-2) is an enzyme expressed in inflammatory reactions. It converts arachidonic acid into prostaglandin-H<sub>2</sub>, the early step in the biosynthesis of proinflammatory lipids



called prostanoids. The other isoform of the enzyme (COX-1) is constitutively expressed in several tissues and plays a key role in maintaining the homeostasis in normal cells [220].


COX-1 and COX-2 are well-known molecular targets for nonsteroidal anti-inflammatory drugs (NSAIDs), and have been investigated in neuroinflammatory conditions such as Alzheimer's disease (AD) [221]. The pathophysiology of AD involves the accumulation of amyloidogenic A $\beta$  peptides within the brain which leads to mitochondrial dysfunction, oxidative stress, and ultimately to neurodegeneration [222]. Accordingly, inhibition of amyloid deposition and destabilization of amyloid aggregates have been investigated in AD drug discovery [223].

Recently, a series of selective COX-2 inhibitors acting as  $\beta$ -amyloid aggregation blockers was discovered via molecular docking [224]. Based on the structure of a diaryltriazine lead (compound 11, Figure 16), a series of derivatives was designed and docked into the active site of both COX-1 (PDB 3N8Z, 2.90 Å) and COX-2 (PDB 3NT1, 1.73 Å) (Figure 17) using AutoDock4.2. The presence of key molecular interactions and the calculated binding free energy were used to evaluate the reliability of the predicted enzyme-inhibitor complexes. All compounds demonstrated higher affinity for COX-2 than for COX-1, as shown by the Gibbs free energy of binding (−8.66 to −9.49 kcal/mol for COX-2 and −0.65 to −5.25 kcal/mol for COX-1). The inhibitors showed the expected molecular interactions, particularly with the so-called selectivity site, where Arg513 plays a critical role in selective COX-2 inhibition.



**Figure 16.** Structure and biological activity of the designed series of COX inhibitors.

Among the designed series, one can highlight compound 14 which showed an  $IC_{50}$  value of 10.1  $\mu\text{M}$  in the COX-2 inhibition assay, with a selectivity index of 8.79. Additionally, this inhibitor displayed remarkable *in vitro* disaggregation activity on  $\beta$ -amyloid peptides (94% inhibition for A $\beta_{1-40}$  and 93% for A $\beta_{1-42}$ ). The ability to selectively inhibit COX-2 while maintaining residual activity on COX-1, along with the potent anti-aggregation activity on A $\beta$  peptides, indicate the suitability of compound 14 as a promising starting point for molecular optimization in AD drug discovery.



**Figure 17.** (A) Structure of the COX inhibitor flurbiprofen; (B) Crystallographic structure of COX-1 complexed to flurbiprofen (PDB 3N8Z, 2.90 Å). The protein backbone is in cartoon representation. The ligand and residues in the active site are shown in stick representation. Hydrogen bonds are indicated as dashed lines; (C) Structure of the COX inhibitor naproxen; (D) Crystallographic structure of COX-2 complexed to naproxen (PDB 3NT1, 1.73 Å). The protein backbone is in cartoon representation. The ligand and residues in the active are shown in stick representation.

## 6. Conclusions

The principles and methods discussed in this review highlight the strategies by which molecular docking and SBDD approaches have been applied in the identification of novel bioactive compounds. Undoubtedly, challenges still remain, especially for issues involving the accuracy of the available scoring functions, which are in fact classical approximations of events ruled by quantum mechanics. Most molecular docking programs successfully predict the binding modes of small-molecule ligands within receptor binding sites. However, the current algorithms do not estimate the absolute energy associated with the intermolecular interaction with satisfactory accuracy. The appropriate handling of issues such as solvent effects, entropic effects, and receptor flexibility are major challenges that require attention. Successful molecular docking protocols require a solid knowledge of the fundamentals of the applied methods. Understanding these principles is essential in the production of meaningful results. Molecular docking has several strengths, among which the method's ability to screen large compound databases at low cost compared to experimental techniques such as HTS is particularly notable. In the current panorama of drug discovery, where high attrition rates are a major concern, properly designed VS strategies are time-saving, cost-effective and productive alternatives. As shown in the highlighted case studies, molecular docking has been able to identify promising compounds that might represent future solutions in critical areas of human health.



## Acknowledgments

We gratefully acknowledge financial support from FAPESP (The State of Sao Paulo Research Foundation, grants: 13/07600-3 and 13/25658-9) and CNPq (The National Council for Scientific and Technological Development).

## Author Contributions

L.G.F.; R.N.S.; G.O.; and A.D.A. contributed equally to the writing of this article.

## Conflicts of Interest

The authors declare no conflict of interest.

## References

1. Hughes, J.P.; Rees, S.; Kalindjian, S.B.; Philpott, K.L. Principles of early drug discovery. *Br. J. Pharmacol.* **2011**, *162*, 1239–1249.
2. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* **2012**, *64*, 4–17.
3. Berman, H.M. The protein data bank. *Nucleic Acids Res.* **2000**, *28*, 235–242.
4. Weigelt, J. Structural genomics-Impact on biomedicine and drug discovery. *Exp. Cell Res.* **2010**, *316*, 1332–1338.
5. Salum, L.; Polikarpov, I.; Andricopulo, A.D. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity. *J. Chem. Inf. Model.* **2008**, *48*, 2243–2253.
6. Kalyaanamoorthy, S.; Chen, Y.P. Structure-based drug design to augment hit discovery. *Drug Discov. Today* **2011**, *16*, 831–839.
7. Acharya, C.; Coop, A.; Polli, J.E.; Mackerell, A.D., Jr. Recent advances in ligand-based drug design: Relevance and utility of the conformationally sampled pharmacophore approach. *Curr. Comput. Aided Drug Des.* **2011**, *7*, 10–22.
8. Bacilieri, M.; Moro, S. Ligand-based drug design methodologies in drug discovery process an overview. *Curr. Drug Discov. Technol.* **2006**, *3*, 155–165.
9. Drwal, M.N.; Griffith, R. Combination of ligand- and structure-based methods in virtual screening. *Drug Discov. Today Technol.* **2013**, *10*, e395–e401.
10. Trossini, G.H.G.; Guido, R.V.C.; Oliva, G.; Ferreira, E.I.; Andricopulo, A.D. Quantitative structure-activity relationships for a series of inhibitors of cruzain from *Trypanosoma cruzi*: Molecular modeling, CoMFA and CoMSIA studies. *J. Mol. Graph. Model.* **2013**, *28*, 3–11.
11. Valasani, K.R.; Vangavaragu, J.R.; Day, V.W.; Yan, S.S. Structure based design, synthesis, pharmacophore modeling, virtual screening, and molecular docking studies for identification of novel cyclophilin D inhibitors. *J. Chem. Inf. Mod.* **2014**, *54*, 902–912.
12. Blaney, J. A very short history of structure-based design: How did we get here and where do we need to go? *J. Comput. Aided Mol. Des.* **2012**, *26*, 13–14.

13. Mandal, S.; Moudgil, M.N.; Mandal, S.K. Rational drug design. *Eur. J. Pharmacol.* **2009**, *625*, 90–100.
14. Urwyler, S. Allosteric modulation of family C G-protein-coupled receptors: From molecular insights to therapeutic perspectives. *Pharmacol. Rev.* **2011**, *63*, 59–126.
15. Wilson, G.L.; Lill, M.A. Integrating structure-based and ligand-based approaches for computational drug design. *Future Med. Chem.* **2011**, *3*, 735–750.
16. Fang, Y. Ligand-receptor interaction platforms and their applications for drug discovery. *Expert Opin. Drug Discov.* **2012**, *7*, 969–988.
17. Kahsai, A.W.; Xiao, K.; Rajagopal, S.; Ahn, S.; Shukla, A.K.; Sun, J.; Oas, T.G.; Lefkowitz, R.J. Multiple ligand-specific conformations of the  $\beta$ 2-adrenergic receptor. *Nat. Chem. Biol.* **2011**, *7*, 692–700.
18. Shoichet, B.K.; Kobilka, B.K. Structure-based drug screening for G-protein-coupled receptors. *Trends Pharmacol. Sci.* **2012**, *33*, 268–272.
19. Chandrika, B.R.; Subramanian, J.; Sharma, S.D. Managing protein flexibility in docking and its applications. *Drug Discov. Today* **2009**, *14*, 394–400.
20. Durrant, J.D.; McCammon, J.A. Computer-aided drug-discovery techniques that account for receptor flexibility. *Curr. Opin. Pharmacol.* **2010**, *10*, 770–774.
21. Meng, X.Y.; Zhang, H.X.; Mezei, M.; Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. *Curr. Comput. Aided Drug Des.* **2011**, *7*, 146–157.
22. López-Vallejo, F.; Caulfield, T.; Martínez-Mayorga, K.; Giulianotti, M.A.; Houghten, R.A.; Nefzi, A.; Medina-Franco, J.L. Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. *Comb. Chem. High Throughput Screen.* **2011**, *14*, 475–487.
23. Huang, S.Y.; Zou, X. Advances and challenges in protein-ligand docking. *Int. J. Mol. Sci.* **2010**, *11*, 3016–3034.
24. Kapetanovic, I.M. Computer-aided drug discovery and development (CADDD): *In silico*-chemico-biological approach. *Chem. Biol. Interact.* **2008**, *171*, 165–176.
25. Yuriev, E.; Agostino, M.; Ramsland, P.A. Challenges and advances in computational docking: 2009 in review. *J. Mol. Recognit.* **2011**, *24*, 149–164.
26. Agrafiotis, D.K.; Gibbs, A.C.; Zhu, F.; Izrailev, S.; Martin, E. Conformational sampling of bioactive molecules: A comparative study. *J. Chem. Inf. Model.* **2007**, *47*, 1067–1086.
27. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Protein-ligand docking: Current status and future challenges. *Proteins Struct. Funct. Bioinform.* **2006**, *65*, 15–26.
28. Zsoldos, Z.; Reid, D.; Simon, A.; Sadjad, S.B.; Johnson, A.P. eHiTS: A new fast, exhaustive flexible ligand docking system. *J. Mol. Graph. Model.* **2007**, *26*, 198–212.
29. Gorelik, B.; Goldblum, A. High quality binding modes in docking ligands to proteins. *Proteins Struct. Funct. Bioinform.* **2008**, *71*, 1373–1386.
30. McGann, M. FRED and HYBRID docking performance on standardized datasets. *J. Comput. Aided Mol. Des.* **2012**, *26*, 897–906.
31. Jain, A.N. Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine. *J. Med. Chem.* **2003**, *46*, 499–511.
32. Ewing, T.J.; Makino, S.; Skillman, A.G.; Kuntz, I.D. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. *J. Comput. Aided Mol. Des.* **2001**, *15*, 411–428.

33. Dias, R.; de Azevedo, J.; Walter, F. Molecular docking algorithms. *Curr. Drug Targets* **2008**, *9*, 1040–1047.
34. Morris, G.M.; Goodsell, D.S.; Huey, R.; Olson, A.J. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. *J. Comput. Aided Mol. Des.* **1996**, *10*, 293–304.
35. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. *J. Mol. Biol.* **1997**, *267*, 727–748.
36. Krovat, E.M.; Steindl, T.; Langer, T. Recent advances in docking and scoring. *Curr. Comput. Aided Drug Des.* **2005**, *1*, 93–102.
37. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shaw, D.E.; Shelley, M.; *et al.* Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J. Med. Chem.* **2004**, *47*, 1739–1749.
38. Pang, Y.P.; Perola, E.; Xu, K.; Prendergast, F.G. EUDOC: A computer program for identification of drug interaction sites in macromolecules and drug leads from chemical databases. *J. Comput. Chem.* **2001**, *22*, 1750–1771.
39. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. *J. Mol. Biol.* **1996**, *261*, 470–489.
40. Welch, W.; Ruppert, J.; Jain, A.N. Hammerhead: Fast, fully automated docking of flexible ligands to protein binding sites. *Chem. Biol.* **1996**, *3*, 449–462.
41. Miller, M.D.; Kearsley, S.K.; Underwood, D.J.; Sheridan, R.P. FLOG: A system to select “quasi-flexible” ligands complementary to a receptor of known three-dimensional structure. *J. Comput. Aided Mol. Des.* **1994**, *8*, 153–174.
42. Schnecke, V.; Kuhn, L.A. Database screening for HIV protease ligands: The influence of binding-site conformation and representation on ligand selectivity. *Proc. Int. Conf. Intell. Syst. Mol. Biol.* **1999**, 242–251.
43. Mizutani, M.Y.; Tomioka, N.; Itai, A. Rational automatic search method for stable docking models of protein and ligand. *J. Mol. Biol.* **1994**, *243*, 310–326.
44. Baxter, C.A.; Murray, C.W.; Clark, D.E.; Westhead, D.R.; Eldridge, M.D. Flexible docking using Tabu search and an empirical estimate of binding affinity. *Proteins* **1998**, *33*, 367–382.
45. Grosdidier, A.; Zoete, V.; Michielin, O. EADock: Docking of small molecules into protein active sites with a multiobjective evolutionary optimization. *Proteins* **2007**, *67*, 1010–1025.
46. Abagyan, R.; Totrov, M.; Kuznetsov, D. ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. *J. Comput. Chem.* **1994**, *15*, 488–506.
47. Venkatachalam, C.M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: A novel method for the shape-directed rapid docking of ligands to protein active sites. *J. Mol. Graph. Model.* **2003**, *21*, 289–307.
48. Sochacka, J. Docking of thiopurine derivatives to human serum albumin and binding site analysis with Molegro Virtual Docker. *Acta Pol. Pharm.* **2014**, *71*, 343–349.
49. Wu, G.; Robertson, D.H.; Brooks, C.L., 3rd; Vieth, M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMM-based MD docking algorithm. *J. Comput. Chem.* **2003**, *24*, 1549–1562.

50. Tietze, S.; Apostolakis, J. GlamDock: Development and validation of a new docking tool on several thousand protein-ligand complexes. *J. Chem. Inf. Model.* **2007**, *47*, 1657–1672.
51. Korb, O.; Stützle, T.; Exner, T.E. Empirical scoring functions for advanced protein-ligand docking with PLANTS. *J. Chem. Inf. Model.* **2009**, *49*, 84–96.
52. Thomsen, R.; Christensen, M.H. MolDock: A new technique for high-accuracy molecular docking. *J. Med. Chem.* **2006**, *49*, 3315–3321.
53. Corbeil, C.R.; Williams, C.I.; Labute, P. Variability in docking success rates due to dataset preparation. *J. Comput. Aided Mol. Des.* **2012**, *26*, 775–786.
54. Foloppe, N.; Hubbard, R. Towards predictive ligand design with free-energy based computational methods? *Curr. Med. Chem.* **2006**, *13*, 3583–3608.
55. Jain, A.N. Scoring functions for protein-ligand docking. *Curr. Protein Pept. Sci.* **2006**, *7*, 407–420.
56. Huang, S.Y.; Grinter, S.Z.; Zou, X. Scoring functions and their evaluation methods for protein-ligand docking: Recent advances and future directions. *Phys. Chem. Chem. Phys.* **2010**, *12*, 12899–12908.
57. Englebienne, P.; Moitessier, N. Docking ligands into flexible and solvated macromolecules. 5. Force-field-based prediction of binding affinities of ligands to proteins. *J. Chem. Inf. Model.* **2009**, *49*, 2564–2571.
58. Kitchen, D.B.; Decornez, H.; Furr, J.R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. *Nat. Rev. Drug Discov.* **2004**, *3*, 935–949.
59. Murray, C.; Auton, T.R.; Eldridge, M.D. Empirical scoring functions. II. The testing of an empirical scoring function for the prediction of ligand-receptor binding affinities and the use of Bayesian regression to improve the quality of the model. *J. Comput. Aided Mol. Des.* **1998**, *12*, 503–519.
60. Eldridge, M.D.; Murray, C.W.; Auton, T.R.; Paolini, G.V.; Mee, R.P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. *J. Comput. Aided Mol. Des.* **1997**, *11*, 425–445.
61. Huang, S.Y.; Zou, X. An iterative knowledge-based scoring function to predict protein-ligand interactions: I. Derivation of interaction potentials. *J. Comput. Chem.* **2006**, *27*, 1866–1875.
62. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. *J. Mol. Biol.* **2000**, *295*, 337–356.
63. Charifson, P.S.; Corkery, J.J.; Murcko, M.A.; Walters, W.P. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. *J. Med. Chem.* **1999**, *42*, 5100–5109.
64. Feher, M. Consensus scoring for protein-ligand interactions. *Drug Discov. Today* **2006**, *11*, 421–428.
65. Terp, G.E.; Johansen, B.N.; Christensen, I.T.; Jørgensen, F.S. A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities. *J. Med. Chem.* **2001**, *44*, 2333–2343.
66. Wang, R.; Lai, L.; Wang, S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. *J. Comput. Aided Mol. Des.* **2002**, *16*, 11–26.
67. Betzi, S.; Suhre, K.; Chétrit, B.; Guerlesquin, F.; Morelli, X. GFScore: A general nonlinear consensus scoring function for high-throughput docking. *J. Chem. Inf. Model.* **2006**, *46*, 1704–1712.
68. Teramoto, R.; Fukunishi, H. Supervised consensus scoring for docking and virtual screening. *J. Chem. Inf. Model.* **2007**, *47*, 526–534.

69. Bar-Haim, S.; Aharon, A.; Ben-Moshe, T.; Marantz, Y.; Senderowitz, H. SeleX-CS: A new consensus scoring algorithm for hit discovery and lead optimization. *J. Chem. Inf. Model.* **2009**, *49*, 623–633.
70. Okamoto, M.; Masuda, Y.; Muroya, A.; Yasuno, K.; Takahashi, O.; Furuya, T. Evaluation of docking calculations on X-ray structures using CONSENSUS-DOCK. *Chem. Pharm. Bull. Tokyo* **2010**, *58*, 1655–1657.
71. Mysinger, M.M.; Shoichet, B.K. Rapid context-dependent ligand desolvation in molecular docking. *J. Chem. Inf. Model.* **2010**, *50*, 1561–1573.
72. Ruvinsky, A.M. Role of binding entropy in the refinement of protein-ligand docking predictions: Analysis based on the use of 11 scoring functions. *J. Comput. Chem.* **2007**, *28*, 1364–1372.
73. Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking. *J. Med. Chem.* **2003**, *46*, 2287–2303.
74. Yin, S.; Biedermannova, L.; Vondrasek, J.; Dokholyan, N.V. MedusaScore: An accurate force field-based scoring function for virtual drug screening. *J. Chem. Inf. Model.* **2008**, *48*, 1656–1662.
75. Rognan, D.; Lauemoller, S.L.; Holm, A.; Buus, S.; Tschinke, V. Predicting binding affinities of protein ligands from three-dimensional models: Application to peptide binding to class I major histocompatibility proteins. *J. Med. Chem.* **1999**, *42*, 4650–4658.
76. Wang, R.; Liu, L.; Lai, L.; Tang, Y. SCORE: A new empirical method for estimating the binding affinity of a protein-ligand complex. *Mol. Model. Annu.* **1998**, *4*, 379–394.
77. Böhm, H.J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. *J. Comput. Aided Mol. Des.* **1994**, *8*, 243–256.
78. Sotriffer, C.A.; Sanschagrin, P.; Matter, H.; Klebe, G. SFCscore: Scoring functions for affinity prediction of protein-ligand complexes. *Proteins Struct. Funct. Bioinform.* **2008**, *73*, 395–419.
79. Reulecke, I.; Lange, G.; Albrecht, J.; Klein, R.; Rarey, M. Towards an integrated description of hydrogen bonding and dehydration: Decreasing false positives in virtual screening with the HYDE scoring function. *ChemMedChem* **2008**, *3*, 885–897.
80. Krammer, A.; Kirchhoff, P.D.; Jiang, X.; Venkatachalam, C.M.; Waldman, M. LigScore: A novel scoring function for predicting binding affinities. *J. Mol. Graph. Model.* **2005**, *23*, 395–407.
81. Gehlhaar, D.K.; Verkhivker, G.M.; Rejto, P.A.; Sherman, C.J.; Fogel, D.B.; Fogel, L.J.; Freer, S.T. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: Conformationally flexible docking by evolutionary programming. *Chem. Biol.* **1995**, *2*, 317–324.
82. DeWitte, R.S.; Shakhnovich, E.I. SMOG: De novo design method based on simple, fast, and accurate free energy estimates. 1. Methodology and supporting evidence. *J. Am. Chem. Soc.* **1996**, *118*, 11733–11744.
83. Muegge, I.; Martin, Y.C.; Hajduk, P.J.; Fesik, S.W. Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. *J. Med. Chem.* **1999**, *42*, 2498–2503.
84. Xie, Z.R.; Hwang, M.J. An interaction-motif-based scoring function for protein-ligand docking. *BMC Bioinform.* **2010**, *11*, 298, doi:10.1186/1471-2105-11-298.
85. Ballester, P.J.; Mitchell, J.B. A machine learning approach to predicting protein-ligand binding affinity with applications to molecular docking. *Bioinformatics* **2010**, *26*, 1169–1175.
86. Das, S.; Krein, M.P.; Breneman, C.M. Binding affinity prediction with property-encoded shape distribution signatures. *J. Chem. Inf. Model.* **2010**, *50*, 298–308.

87. Fan, H.; Schneidman-Duhovny, D.; Irwin, J.J.; Dong, G.; Shoichet, B.K.; Sali, A. Statistical potential for modeling and ranking of protein-ligand interactions. *J. Chem. Inf. Model.* **2011**, *51*, 3078–3092.
88. Kumalo, H.M.; Bhakat, S.; Soliman, M.E. Theory and applications of covalent docking in drug discovery: Merits and pitfalls. *Molecules* **2015**, *20*, 1984–2000.
89. Singh, J.; Petter, R.C.; Baillie, T.A.; Whitty, A. The resurgence of covalent drugs. *Nat. Rev. Drug Discov.* **2011**, *10*, 307–317.
90. Ouyang, X.; Zhou, S.; Su, C.T.T.; Ge, Z.; Li, R.; Kwoh, C.K. CovalentDock: Automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints. *J. Comput. Chem.* **2013**, *34*, 326–336.
91. Moitessier, N.; Englebienne, P.; Lee, D.; Lawandi, J.; Corbeil, C.R. Towards the development of universal, fast and highly accurate docking/scoring methods: A long way to go. *Br. J. Pharmacol.* **2008**, *153*, S7–S26.
92. Xu, M.; Lill, M.A. Induced fit docking, and the use of QM/MM methods in docking. *Drug Discov. Today Technol.* **2013**, *10*, e411–e418.
93. Menikarachchi, L.C.; Gascón, J.A. QM/MM approaches in medicinal chemistry research. *Curr. Top. Med. Chem.* **2010**, *10*, 46–54.
94. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein-ligand docking using GOLD. *Proteins* **2003**, *52*, 609–623.
95. London, N.; Miller, R.M.; Krishnan, S.; Uchida, K.; Irwin, J.J.; Eidam, O.; Cimermančič, P.; Gibold, L.; Bonnet, R.; Shoichet, B.K.; *et al.* Covalent docking of large libraries for the discovery of chemical probes. *Nat. Chem. Biol.* **2014**, *10*, 1066–1072.
96. Bianco, G.; Forli, S.; Goodsell, D.S.; Olson, A.J. Covalent docking using Autodock: Two-point attractor and flexible sidechain methods. *Protein Sci.* **2015**, Epub ahead of print.
97. Lin, J.H. Accommodating protein flexibility for structure-based drug design. *Curr. Top. Med. Chem.* **2011**, *11*, 171–178.
98. Salsbury, F.R., Jr. Molecular dynamics simulations of protein dynamics and their relevance to drug discovery. *Curr. Opin. Pharmacol.* **2010**, *10*, 738–744.
99. Durrant, J.D.; McCammon, J.A. Molecular dynamics simulations and drug discovery. *BMC Biol.* **2011**, *9*, doi:10.1186/1741-7007-9-71.
100. Harvey, M.J.; de Fabritiis, G. High-throughput molecular dynamics: The powerful new tool for drug discovery. *Drug Discov. Today* **2012**, *17*, 1059–1062.
101. Alonso, H.; Bliznyuk, A.A.; Gready, J.E. Combining docking and molecular dynamic simulations in drug design. *Med. Res. Rev.* **2006**, *26*, 531–568.
102. Chen, Y.C. Beware of docking! *Trends Pharmacol. Sci.* **2015**, *36*, 78–95.
103. Nichols, S.E.; Baron, R.; Ivetac, A.; McCammon, J.A. Predictive power of molecular dynamics receptor structures in virtual screening. *J. Chem. Inf. Model.* **2011**, *51*, 1439–1446.
104. Cornell, W.D.; Cieplak, P.; Bayly, C.I.; Gould, I.R.; Merz, K.M.; Ferguson, D.M.; Spellmeyer, D.C.; Fox, T.; Caldwell, J.W.; Kollman, P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. *J. Am. Chem. Soc.* **1995**, *117*, 5179–5197.

105. Brooks, B.R.; Brucoleri, R.E.; Olafson, B.D.; States, D.J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. *J. Comp. Chem.* **1983**, *4*, 187–217.
106. Christen, M.; Hünenberger, P.H.; Bakowies, D.; Baron, R.; Bürgi, R.; Geerke, D.P.; Heinz, T.N.; Kastenholtz, M.A.; Kräutler, V.; Oostenbrink, C.; *et al.* The GROMOS software for biomolecular simulation: GROMOS05. *J. Comput. Chem.* **2005**, *26*, 1719–1751.
107. Sousa, S.F.; Ribeiro, A.J.; Coimbra, J.; Neves, R.P.; Martins, S.A.; Moorthy, N.S.; Fernandes, P.A.; Ramos, M.J. Protein-ligand docking in the new millennium—A retrospective of 10 years in the field. *Curr. Med. Chem.* **2013**, *20*, 2296–2314.
108. Klebe, G. Virtual ligand screening: Strategies, perspectives and limitations. *Drug Discov. Today* **2006**, *11*, 580–594.
109. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist’s guide to molecular interactions. *J. Med. Chem.* **2010**, *53*, 5061–5084.
110. Michel, J.; Tirado-Rives, J.; Jorgensen, W.L. Energetics of displacing water molecules from protein binding sites: Consequences for ligand optimization. *J. Am. Chem. Soc.* **2009**, *131*, 15403–15411.
111. Amadasi, A.; Surface, J.A.; Spyraakis, F.; Cozzini, P.; Mozzarelli, A.; Kellogg, G.E. Robust classification of “relevant” water molecules in putative protein binding sites. *J. Med. Chem.* **2008**, *51*, 1063–1067.
112. Amadasi, A.; Spyraakis, F.; Cozzini, P.; Abraham, D.J.; Kellogg, G.E.; Mozzarelli, A. Mapping the energetics of water-protein and water-ligand interactions with the “natural” HINT forcefield: Predictive tools for characterizing the roles of water in biomolecules. *J. Mol. Biol.* **2006**, *358*, 289–309.
113. Kellogg, G.E.; Chen, D.L. The importance of being exhaustive. Optimization of bridging structural water molecules and water networks in models of biological systems. *Chem. Biodivers.* **2004**, *1*, 98–105.
114. Gonzalez, M.W.; Kann, M.G. Chapter 4: Protein interactions and disease. *PLoS Comput. Biol.* **2012**, *8*, e1002819.
115. Arkin, M.R.; Wells, J.A. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. *Nat. Rev. Drug Discov.* **2004**, *3*, 301–317.
116. Wells, J.A.; McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. *Nature* **2007**, *450*, 1001–1009.
117. Sun, D.; Li, Z.; Rew, Y.; Gribble, M.; Bartberger, M.D.; Beck, H.P.; Canon, J.; Chen, A.; Chen, X.; Chow, D.; *et al.* Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. *J. Med. Chem.* **2014**, *57*, 1454–1472.
118. Kuritzkes, D.; Kar, S.; Kirkpatrick, P. Maraviroc. *Nat. Rev. Drug Discov.* **2008**, *7*, 15–16.
119. Fuller, J.C.; Burgoyne, N.J.; Jackson, R.M. Predicting druggable binding sites at the protein-protein interface. *Drug Discov. Today* **2009**, *14*, 155–161.
120. Laurie, A.T.; Jackson, R.M. Q-SiteFinder: An energy-based method for the prediction of protein-ligand binding sites. *Bioinformatics* **2005**, *21*, 1908–1916.
121. Meireles, L.M.; Dömling, A.S.; Camacho, C.J. ANCHOR: A web server and database for analysis of protein-protein interaction binding pockets for drug discovery. *Nucleic Acids Res.* **2010**, *38*, W407–W411.

122. Camacho, C.J.; Zhang, C. FastContact: Rapid estimate of contact and binding free energies. *Bioinformatics* **2005**, *21*, 2534–2536.
123. Moreira, I.S.; Fernandes, P.A.; Ramos, M.J. Protein-protein docking dealing with the unknown. *J. Comput. Chem.* **2010**, *31*, 317–342.
124. Dominguez, C.; Boelens, R.; Bonvin, A.M. HADDOCK: A protein-protein docking approach based on biochemical or biophysical information. *J. Am. Chem. Soc.* **2003**, *125*, 1731–1737.
125. Lyne, P.D. Structure-based virtual screening an overview. *Drug Discov. Today* **2002**, *7*, 649–657.
126. Stahura, F.L.; Bajorath, J. Virtual screening methods that complement HTS. *Comb. Chem. High Throughput Screen.* **2004**, *7*, 259–269.
127. Kodadek, T. The rise, fall and reinvention of combinatorial chemistry. *Chem. Commun.* **2011**, *47*, 9757–9763.
128. Oprea, T.I.; Matter, H. Integrating virtual screening in lead discovery. *Curr. Opin. Chem. Biol.* **2004**, *8*, 349–358.
129. Geppert, H.; Vogt, M.; Bajorath, J. Current trends in ligand-based virtual screening: Molecular representations, data mining methods, new application areas, and performance evaluation. *J. Chem. Inf. Model.* **2010**, *50*, 205–216.
130. Ripphausen, P.; Nisius, B.; Bajorath, J. State-of-the-art in ligand-based virtual screening. *Drug Discov. Today* **2011**, *16*, 372–376.
131. Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E.W., Jr. Computational methods in drug discovery. *Pharmacol. Rev.* **2013**, *66*, 334–395.
132. Inglese, J.; Auld, D.S.; Jadhav, A.; Johnson, R.L.; Simeonov, A.; Yasgar, A.; Zheng, W.; Austin, C.P. Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 11473–11478.
133. Molinspiration Cheminformatics. Available online: <http://www.molinspiration.com/> (accessed on 9 May 2015).
134. Jarrahpour, A.; Fathi, J.; Mimouni, M.; Hadda, T.B.; Sheikh, J.; Chohan, Z.; Parvez, A. Petra, Osiris and Molinspiration (POM) together as a successful support in drug design: Antibacterial activity and biopharmaceutical characterization of some azo Schiff bases. *Med. Chem. Res.* **2012**, *21*, 1984–1990.
135. Organic Chemistry Portal. Available online: <http://www.organic-chemistry.org/prog/peo/> (accessed on 9 May 2015).
136. Molsoft. Available online: <http://molsoft.com/> (accessed on 9 May 2015).
137. Molecular Discovery. Available online: <http://www.moldiscovery.com/software/moka/> (accessed on 9 May 2015).
138. Milletti, F.; Storchi, L.; Sforna, G.; Cruciani, G. New and original pKa prediction method using grid molecular interaction fields. *J. Chem. Inf. Model.* **2007**, *47*, 2172–2181.
139. Spitzer, G.M.; Heiss, M.; Mangold, M.; Markt, P.; Kirchmair, J.; Wolber, G.; Liedl, K.R. One concept, three implementations of 3D pharmacophore-based virtual screening: Distinct coverage of chemical search space. *J. Chem. Inf. Model.* **2010**, *50*, 1241–1247.
140. Wolber, G.; Seidel, T.; Bendix, F.; Langer, T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. *Drug Discov. Today* **2008**, *13*, 23–29.



141. Pharmacophore and ligand-based design with Biovia Discovery Studio<sup>®</sup> datasheet. Available online: <http://accelrys.com/products/datasheets/pharmacophore-modeling.pdf> (accessed on 9 May 2015).
142. Jones, G.; Willett, P.; Glen, R.C. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. *J. Comput. Aided Mol. Des.* **1995**, *9*, 532–549.
143. Certara. Available online: <http://www.certara.com/> (accessed on 9 May 2015).
144. Martin, Y.C.; Bures, M.G.; Danaher, E.A.; DeLazzer, J.; Lico, I.; Pavlik, P.A. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. *J. Comput. Aided Mol. Des.* **1993**, *7*, 83–102.
145. Richmond, N.J.; Abrams, C.A.; Wolohan, P.R.N.; Abrahamian, E.; Willett, P.; Clark, R.D. GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. *J. Comput. Aided Mol. Des.* **2006**, *20*, 567–587.
146. Wolber, G.; Langer, T. LigandScout: 3-D Pharmacophores derived from protein-bound ligands and their use as virtual screening filters. *J. Chem. Inf. Model.* **2004**, *45*, 160–169.
147. Inteligand. Available online: <http://www.inteligand.com/> (accessed on 9 May 2015).
148. Chemical Computing Group. Available online: <https://www.chemcomp.com/> (accessed on 9 May 2015).
149. Labute, P.; Williams, C.; Feher, M.; Sourial, E.; Schmidt, J.M. Flexible alignment of small molecules. *J. Med. Chem.* **2001**, *44*, 1483–1490.
150. Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. *J. Comput. Aided Mol. Des.* **2006**, *20*, 10–11.
151. Schrodinger. Available online: <http://www.schrodinger.com/> (accessed on 9 May 2015).
152. Cresset. Available online: <http://www.cresset-group.com/> (accessed on 9 May 2015).
153. Vinter, J.G. Extended electron distributions applied to the molecular mechanics of some intermolecular interactions. *J. Comput. Aided Mol. Des.* **1994**, *8*, 653–668.
154. PharmaGist. Available online: <http://bioinfo3d.cs.tau.ac.il/PharmaGist/> (accessed on 9 May 2015).
155. Schneidman-Duhovny, D.; Dror, O.; Inbar, Y.; Nussinov, R.; Wolfson, H.J. PharmaGist: A webserver for ligand-based pharmacophore detection. *Nucleic Acids Res.* **2008**, *36*, W223–W228.
156. Van Drie, J.H.; Weininger, D.; Martin, Y.C. ALADDIN: An integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures. *J. Comput. Aided Mol. Des.* **1989**, *3*, 225–251.
157. Hoffmann, C.M.; Finn, P.W.; Kaviraki, L.E.; Latombe, J.C.; Motwani, R.; Venkatasubramanian, S.; Shelton, C.; Yao, A. RAPID: Randomized pharmacophore identification for drug design. *Comp. Geom.* **1998**, *4*, 263–272.
158. Van Drie, J.H. Strategies for the determination of pharmacophoric 3D database queries. *J. Comput. Aided Mol. Des.* **1997**, *11*, 39–52.
159. Diaz-Arauzo, H.; Koehler, K.F.; Hagen, T.J.; Cook, J.M. Synthetic and computer assisted analysis of the pharmacophore for agonists at benzodiazepine receptors. *Life Sci.* **1991**, *49*, 207–216.
160. Dolata, D.P.; Parrill, A.L.; Walters, W.P. CLEW: The generation of pharmacophore hypotheses through machine learning. *SAR QSAR Environ. Res.* **1998**, *9*, 53–81.
161. Holliday, J.D.; Willett, P. Using a genetic algorithm to identify common structural features in sets of ligands. *J. Mol. Graph. Model.* **1997**, *15*, 221–232.

162. Handschuh, S.; Wagener, M.; Gasteiger, J. Superposition of three-dimensional chemical structures allowing for conformational flexibility by a hybrid method. *J. Chem. Inf. Comput. Sci.* **1998**, *38*, 220–232.
163. Chen, X.; Rusinko, A., 3rd; Tropsha, A.; Young, S.S. Automated pharmacophore identification for large chemical data sets. *J. Chem. Inf. Comput. Sci.* **1999**, *39*, 887–896.
164. Talele, T.T.; Kulkarni, V.M. Three-dimensional quantitative structure-activity relationships (QSAR) and receptor mapping of cytochrome P-45014 $\alpha$ DM inhibiting azole antifungal agents. *J. Chem. Inf. Comput. Sci.* **1999**, *39*, 204–210.
165. Wang, R.; Gao, Y.; Lai, L. LigBuilder: A multi-purpose program for structure-based drug design. *J. Mol. Model.* **2000**, *6*, 498–516.
166. LigBuilder. Available online: [ligbuilder.org](http://ligbuilder.org) (accessed on 18 June 2015).
167. Lionta, E.; Spyrou, G.; Vassilatis, D.K.; Cournia, Z. Structure-based virtual screening for drug discovery: Principles, applications and recent advances. *Curr. Top. Med. Chem.* **2014**, *14*, 1923–1938.
168. Gangwal, R.P.; Damre, M.V.; Das, N.R.; Dhoke, G.V.; Bhadauriya, A.; Varikoti, R.A.; Sharma, S.S.; Sangamwar, A.T. Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors. *J. Mol. Graph. Model.* **2015**, *57*, 89–98.
169. Scior, T.; Bender, A.; Tresadern, G.; Medina-Franco, J.L.; Martínez-Mayorga, K.; Langer, T.; Cuanalo-Contreras, K.; Agrafiotis, D.K. Recognizing pitfalls in virtual screening: A critical review. *J. Chem. Inf. Model.* **2012**, *52*, 867–881.
170. Cavasotto, C.N.; Orry, W.; Andrew, J. Ligand docking and structure-based virtual screening in drug discovery. *Curr. Top. Med. Chem.* **2007**, *7*, 1006–1014.
171. Kirchmair, J.; Markt, P.; Distinto, S.; Wolber, G.; Langer, T. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn from earlier mistakes? *J. Comput. Aided Mol. Des.* **2008**, *22*, 213–228.
172. Jain, A.N.; Nicholls, A. Recommendations for evaluation of computational methods. *J. Comput. Aided Mol. Des.* **2008**, *22*, 133–139.
173. Moura Barbosa, A.J.; del Rio, A. Freely accessible databases of commercial compounds for high-throughput virtual screenings. *Curr. Top. Med. Chem.* **2012**, *12*, 866–877.
174. Sastry, M.; Lowrie, J.F.; Dixon, S.L.; Sherman, W. Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments. *J. Chem. Inf. Model.* **2010**, *50*, 771–784.
175. Irwin, J.J.; Sterling, T.; Mysinger, M.M.; Bolstad, E.S.; Coleman, R.G. ZINC: A free tool to discover chemistry for biology. *J. Chem. Inf. Model.* **2012**, *52*, 1757–1768.
176. ZINC. Available online: [zinc.docking.org](http://zinc.docking.org) (accessed on 9 May 2015).
177. PubChem. Available online: [pubchem.ncbi.nlm.nih.gov](http://pubchem.ncbi.nlm.nih.gov) (accessed on 9 May 2015).
178. Li, Q.; Cheng, T.; Wang, Y.; Bryant, S.H. PubChem as a public resource for drug discovery. *Drug Discov. Today* **2010**, *15*, 1052–1057.
179. ChemSpider. Available online: [www.chemspider.com](http://www.chemspider.com) (accessed on 9 May 2015).
180. Pence, H.E.; Williams, A. ChemSpider: An online chemical information resource. *J. Chem. Educ.* **2010**, *87*, 1123–1124.
181. ChEMBL. Available online: [www.ebi.ac.uk/chembl](http://www.ebi.ac.uk/chembl) (accessed on 9 May 2015).

182. Bento, A.P.; Gaulton, A.; Hersey, A.; Bellis, L.J.; Chambers, J.; Davies, M.; Krüger, F.A.; Light, Y.; Mak, L.; McGlinchey, S.; *et al.* The ChEMBL bioactivity database: An update. *Nucleic Acids Res.* **2014**, *42*, D1083–D1090.
183. Núcleo de Bioensaios Biossíntese e Ecofisiologia de Produtos Naturais. Available online: <http://nubbe.iq.unesp.br/portal/> (accessed on 9 May 2015).
184. Valli, M.; dos Santos, R.N.; Figueira, L.D.; Nakajima, C.H.; Castro-Gamboa, I.; Andricopulo, A.D.; Bolzani, V.S. Development of a natural products database from the biodiversity of Brazil. *J. Nat. Prod.* **2013**, *76*, 439–444.
185. ChemBank. Available online: [chembank.broadinstitute.org](http://chembank.broadinstitute.org) (accessed on 9 May 2015).
186. Seiler, K.P.; George, G.A.; Happ, M.P.; Bodycombe, N.E.; Carrinski, H.A.; Norton, S.; Brudz, S.; Sullivan, J.P.; Muhlich, J.; Serrano, M.; *et al.* ChemBank: A small-molecule screening and cheminformatics resource database. *Nucleic Acids Res.* **2008**, *36*, D351–D359.
187. eMolecules. Available online: [www.emolecules.com](http://www.emolecules.com) (accessed on 9 May 2015).
188. DrugBank. Available online: [drugbank.ca](http://drugbank.ca) (accessed on 9 May 2015).
189. Wishart, D.S.; Knox, C.; Guo, A.C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: A comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res.* **2006**, *34*, D668–D672.
190. The Binding Database. Available online: [www.bindingdb.org/bind/index.jsp](http://www.bindingdb.org/bind/index.jsp) (accessed on 9 May 2015).
191. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R.N.; Gilson, M.K. BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities. *Nucleic Acids Res.* **2007**, *35*, D198–D201.
192. Akdemir, A.; Rucktooa, P.; Jongejan, A.; van Elk, R.; Bertrand, S.; Sixma, T.K.; de Esch, I.J. Acetylcholine binding protein (AChBP) as template for hierarchical in silico screening procedures to identify structurally novel ligands for the nicotinic receptors. *Bioorganic Med. Chem.* **2011**, *19*, 6107–6119.
193. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A visualization system for exploratory research and analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612.
194. UCSF Chimera. Available online: <http://www.cgl.ucsf.edu/chimera/> (accessed on 9 May 2015).
195. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. *J. Mol. Graph.* **1996**, *14*, 33–38.
196. VMD Visual Molecular Dynamics. Available online: <http://www.ks.uiuc.edu/Research/vmd> (accessed on 9 May 2015).
197. Pymol. Available online: <http://www.pymol.org/> (accessed on 9 May 2015).
198. Lill, M.A.; Danielson, M.L. Computer-aided drug design platform using PyMOL. *J. Comput. Aided Mol. Des.* **2011**, *25*, 13–19.
199. Ball Biochemical Algorithms Library. Available online: <http://www.ball-project.org/> (accessed on 9 May 2015).
200. Moll, A.; Hildebrandt, A.; Lenhof, H.P.; Kohlbacher, O. BALLView: A tool for research and education in molecular modeling. *Bioinformatics* **2006**, *22*, 365–366.
201. Home Page for RasMol and OpenRasMol. Available online: <http://www.rasmol.org/> (accessed on 9 May 2015).

202. Sayle, R.A.; Milner-White, E.J. RASMOL: Biomolecular graphics for all. *Trends Biochem. Sci.* **1995**, *20*, 374–376.
203. Jmol: An open-source Java viewer for chemical structures in 3D. Available online: <http://www.jmol.org/> (accessed on 18 June 2015).
204. JSmol. Available online: <http://wiki.jmol.org/index.php/JSmol> (accessed on 18 June 2015).
205. Molle, V.; Gulten, G.; Vilchèze, C.; Veyron-Churlet, R.; Zanella-Cléon, I.; Sacchettini, J.C.; Jacobs, W.R., Jr.; Kremer, L. Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of *Mycobacterium tuberculosis*. *Mol. Microbiol.* **2010**, *78*, 1591–1605.
206. Marrakchi, H.; Lanéelle, G.; Quémard, A. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. *Microbiology* **2000**, *146*, 289–296.
207. Pauli, I.; dos Santos, R.N.; Rostirolla, D.C.; Martinelli, L.K.; Ducati, R.G.; Timmers, L.F.S.M.; Basso, L.A.; Santos, D.S.; Guido, R.V.C.; Andricopulo, A.D.; *et al.* Discovery of new inhibitors of *Mycobacterium tuberculosis* InhA enzyme using virtual screening and a 3D-pharmacophore-based approach. *J. Chem. Inf. Model.* **2013**, *53*, 2390–2401.
208. Abrahamian, E.; Fox, P.C.; Naerum, L.; Christensen, I.T.; Thøgersen, H.; Clark, R.D. Efficient generation, storage, and manipulation of fully flexible pharmacophore multiplets and their use in 3-D similarity searching. *J. Chem. Inf. Comput. Sci.* **2003**, *43*, 458–468.
209. Adams, J. The proteasome: Structure, function, and role in the cell. *Cancer Treat. Rev.* **2003**, *29*, 3–9.
210. Miller, Z.; Kim, K.S.; Lee, D.M.; Kasam, V.; Baek, S.E.; Lee, K.H.; Zhang, Y.Y.; Ao, L.; Carmony, K.; Lee, N.R.; *et al.* Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening. *J. Med. Chem.* **2015**, *58*, 2036–2041.
211. Mitchell, T.J.; John, S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. *Immunology* **2005**, *114*, 301–312.
212. Timofeeva, O.A.; Tarasova, N.I.; Zhang, X.; Chasovskikh, S.; Cheema, A.K.; Wang, H.; Brown, M.L.; Dritschilo, A. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 1267–1272.
213. Matsuno, K.; Masuda, Y.; Uehara, Y.; Sato, H.; Muroya, A.; Takahashi, O.; Yokotagawa, T.; Furuya, T.; Okawara, T.; Otsuka, M.; Ogo, N.; *et al.* Identification of a new series of STAT3 inhibitors by virtual screening. *ACS Med. Chem. Lett.* **2010**, *1*, 371–375.
214. Bachmann, M.; Möröy, T. The serine/threonine kinase Pim-1. *Int. J. Biochem. Cell Biol.* **2005**, *37*, 726–730.
215. Blanco-Aparicio, C.; Carnero, A. Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. *Biochem. Pharmacol.* **2013**, *85*, 629–643.
216. Ren, J.X.; Li, L.L.; Zheng, R.L.; Xie, H.Z.; Cao, Z.X.; Feng, S.; Pan, Y.L.; Chen, X.; Wei, Y.Q.; Yang, S.Y. Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking. *J. Chem. Inf. Model.* **2011**, *51*, 1364–1375.
217. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. *Nature* **2001**, *414*, 813–820.
218. Srivastava, S.K.; Ramana, K.V.; Bhatnagar, A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. *Endocr. Rev.* **2005**, *26*, 380–392.

219. Wang, L.; Gu, Q.; Zheng, X.; Ye, J.; Liu, Z.; Li, J.; Hu, X.; Hagler, A.; Xu, J. Discovery of new selective human aldose reductase inhibitors through virtual screening multiple binding pocket conformations. *J. Chem. Inf. Model.* **2013**, *53*, 2409–2422.
220. Perrone, M.G.; Scilimati, A.; Simone, L.; Vitale, P. Selective COX-1 inhibition: A therapeutic target to be reconsidered. *Curr. Med. Chem.* **2010**, *17*, 3769–3805.
221. Wang, P.; Guan, P.P.; Wang, T.; Yu, X.; Guo, J.J.; Wang, Z.Y. Aggravation of Alzheimer's disease due to the COX-2-mediated reciprocal regulation of IL-1 $\beta$  and A $\beta$  between glial and neuron cells. *Aging Cell* **2014**, *13*, 605–615.
222. Abramov, A.Y.; Canevari, L.; Duchen, M.R. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. *J. Neurosci.* **2004**, *24*, 565–575.
223. Wyss-Coray, T.; Rogers, J. Inflammation in Alzheimer disease—a brief review of the basic science and clinical literature. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a006346.
224. Dadashpour, S.; Tuylu Kucukkilinc, T.; Unsal Tan, O.; Ozadali, K.; Irannejad, H.; Emami, S. Design, synthesis and *in vitro* study of 5,6-diaryl-1,2,4-triazine-3-ylthioacetate derivatives as COX-2 and  $\beta$ -amyloid aggregation inhibitors. *Arch. Pharm.* **2015**, *348*, 179–187.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).